Endocrinology, Vol 107, 328-333, Copyright © 1980 by Endocrine Society

ARTICLES

Comparative therapeutic effects of vitamin D3 and its derivatives on experimental renal osteodystrophy

M Fukushima, R Niki, H Ohkawa, T Shimizu, I Matsunaga, H Nakano, Y Takagaki, Y Nishii, K Okano and T Suda

The comparative effectiveness of vitamin D3 and its derivatives in curing hyperparathyroidism and osteodystrophic bone lesions was examined in a laboratory model of renal osteodystrophy associated with marked secondary hyperparathyroidism in rats. The experimental model was prepared by a single injection of homologous glycopeptide. Plasma levels of 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3] appeared to decrease in the rats receiving glycopeptide. Various doses of vitamin D3 derivatives [2 or 10 microgram/kg D3, 2 microgram/kg 25- hydroxyvitamin D3 (25OHD3), 0.1 microgram/kg 1 alpha,25(OH)2D3, and 0.1 or 0.2 microgram/kg 1 alpha-hydroxyvitamin D3 (1 alpha OHD3)] were daily administered orally to the nephritic rats for 23 days before sacrifice. 1 alpha,25(OH)2D3 and 1 alpha OHD3 were much more potent than 25OHD3 and D3 in reducing the hyperplasia of parathyroir glands. The potency of 1 alpha OHD3 in curing the histological changes of osteodystrophy appeared to be greater than that of 1 alpha,25(OH)2D3. The same dose level of 1 alpha OHD3 was more effective than 1 alpha,25(OH)2D3 in enhancing plasma 1 alpha,25(OH)2D3 levels.

This article has been cited by other articles:

				K. Tamagaki, Q. Yuan, H. Ohkawa, I. Imazeki, Y. Moriguchi, N. Imai, S. Sasaki, K. Takeda, and M. Fukagawa Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia Nephrol. Dial. Transplant., March 1, 2006; 21(3): 651 - 659. [Abstract] [Full Text] [PDF]